• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Cold Chain Packaging and Logistics

    How Artificial Intelligence and Machine Learning are Transforming the Life Sciences

    Challenges of Preparing Highly Potent Oral Products

    Bioprocessing Trends

    Sustainable Manufacturing
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    groninger Continues Growth in the US

    Catalent Bolsters Cell and Gene Services
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    What Does the Future of API Synthesis Look Like?

    Pasithea Signs CMC Development and Manufacturing Agreement

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Jaguar Health Achieves Key Milestone for Crofelemer API Manufacturer
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Bolsters Cell and Gene Services

    CDMO Sirio Pharma Completes the Acquisition of Best Formulations

    Meeting the Container Closure Integrity Requirements in the Revised EU Annex 1

    Case Study: Secondary Sourcing Strategies to Ensure Supply Chain Security

    Beat the Supply Chain Backlog
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Experic Expands Analytical Capabilities and Facilities

    List Labs Expands Manufacturing Capacity

    Catalent Bolsters Cell and Gene Services

    Crown Bioscience to Acquire Indivumed’s Service Biz and Supporting Biobank

    Stevanato Group, Transcoject Partner on Pre-Fillable Syringe Polymer Options
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Adare Partners with Veeva to Strengthen Quality Operations

    KBI Secures Swissmedic Regulatory Establishment License for Facility in Geneva

    Enhancing Ease of Use, Batch Turnaround, and Process Flexibility

    Understanding the Essential Role of a Qualified Person

    Altasciences Los Angeles Clinical Site Receives CAP Accreditation
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    INCOG BioPharma Services

    LOTTE BIOLOGICS

    Almac Group

    Alcami

    Syngene International Ltd.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    INCOG BioPharma Services

    LOTTE BIOLOGICS

    Almac Group

    Alcami

    Syngene International Ltd.
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    Biogen

    ...

    Biogen
    Biogen
    Related CONTENT
    • pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    • Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    • Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients
    • First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    • Thermo Fisher Launches Gibco AAV Production System
    07.16.21
    Headquarters: Cambridge, MA
    twitter.com/biogen
    www.biogen.com


    Headcount:  9,100
    Year Established:  1986
    Revenues:  $13,445  (-7%)
    Net Income:  $4,001          (-32%)
    R&D:  $3,991  (+75%)

    TOP SELLING DRUGS  
    Drug Indication 2020 Sales (+/-%)
    Fumarate  multiple sclerosis $3,905 -12%
    Spinraza Spinal muscular atrophe  $2,052 -2.1
    TYSABRI multiple sclerosis $1,946 3%
    Interferon  multiple sclerosis $1,878 -11
    BENEPALI Arthritis, psoriasis $482  -1%
    IMRALDI  Arthritis, rheumatoid $216 18%
    FAMPYRA  Multiple sclerosis $103 6%
    FLIXABI  Arthritis, rheumatoid $98 43%
    FUMADERM Psoriasis $12 -20%


    Biogen, focused on innovative therapies for serious neurological and neurodegenerative diseases, as well as related therapeutic adjacencies, has 10 programs either in Phase 3 or filed with regulatory agencies, including in Alzheimer’s disease, neuropsychiatry, amyotrophic lateral sclerosis (ALS) and ophthalmology.

    In 2020, the company added or advanced 12 clinical programs, bolstering its early- and late-stage pipelines through both internal development and collaborations.

    In March 2020, Biogen acquired BIIB118 (CK1 inhibitor), a novel CNS-penetrant small molecule inhibitor of casein kinase 1, for the potential treatment of behavioral and neurological symptoms across various psychiatric and neurological diseases, from Pfizer. The company is developing BIIB118 for the potential treatment of irregular sleep wake rhythm disorder (ISWRD) in Parkinson’s disease and plans to develop BIIB118 for the potential treatment of sundowning in Alzheimer's disease.

    In April 2020 Biogen closed a collaboration and license agreement with Sangamo Therapeutics, Inc. to develop and commercialize ST-501 for tauopathies, including Alzheimer’s disease; ST-502 for synucleinopathies, including, Parkinson’s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases.

    Biogen also closed a collaboration and license agreement with Denali Therapeutics to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease. In addition to the LRRK2 program, it also has an exclusive option to license two preclinical programs from Denali’s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled antiamyloid beta (Abeta) program and a second program utilizing its Transport Vehicle technology. Further, Biogen has a right of first negotiation on two additional Transport Vehicle-enabled therapeutics.

    In December 2020 Biogen closed a global collaboration and license agreement with Sage Therapeutics, Inc. to jointly develop and commercialize zuranolone for the potential treatment of major depressive disorder, postpartum depression and other psychiatric disorders, and SAGE-324 for the potential treatment of essential tremor and other neurological disorders.

    Of Biogen’s advancing assets, the EMA accepted for review the MAA for SB11, and the FDA accepted the BLA for SB11. Biogen has exclusive rights to commercialize SB11 in major markets pursuant to its 2019 agreement with Samsung Bioepis. SB11 is a proposed ranibizumab biosimilar referencing Lucentis.

    Possibly the biggest news of the last year was the recent FDA approval of aducanumab, the first novel therapy for Alzheimer’s disease approved since 2003. Biogen and Japanese partner Eisai developed aducanumab, administered through intravenous infusion to treat early Alzheimer's disease. The drug was developed for mild cognitive impairment, not severe dementia. 
    Related Searches
    • hpapis
    • hollister stier
    • aims to enhance clinical research
    • pharmaceutical packaging
    Suggested For You
    pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray
    Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany
    Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients  Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients
    First Patient is Dosed with Triumvira First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy
    Thermo Fisher Launches Gibco AAV Production System Thermo Fisher Launches Gibco AAV Production System
    Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact Everest Medicines, Sinovent, SinoMab Enter Global BTK Inhibitor Mfg. Pact
    Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention Lilly’s Antibody Treatment Gets EUA for Post-Exposure COVID Prevention
    Asychem Partners with LaNova Medicines Asychem Partners with LaNova Medicines
    Tevogen Completes Tech Transfer to CDMO BioCentriq Tevogen Completes Tech Transfer to CDMO BioCentriq
    Clean Cells Expands Bioproduction Capabilities Clean Cells Expands Bioproduction Capabilities
    Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals Catalent Signs Commercial Supply Agreement with Phathom Pharmaceuticals
    U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail U.S. Govt. to Purchase Additional Doses of REGEN-COV Antibody Cocktail
    Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co. Hookipa Enters Clinical Collaboration & Supply Agreement with Merck & Co.
    U.S. Govt. Purchases Additional Doses of Lilly U.S. Govt. Purchases Additional Doses of Lilly's Antibody Therapies for COVID
    CEO Spotlight: Gaston Salinas, Botanical Solution Inc. CEO Spotlight: Gaston Salinas, Botanical Solution Inc.

    Related Breaking News

    • Breaking News | Clinical Trials
      pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray

      pHOXBIO Unveils Trial Results from COVID Prophylactic Nasal Spray

      According to the study, the novel prophylactic nasal spray prevented infection from SARS-CoV-2, the virus that causes COVID-19.
      09.22.21

    • Biologics, Proteins, Vaccines | Breaking News | Clinical Trials
      Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany

      Immunic Inc. Signs In-License Agreement with University Medical Center Goettingen, Germany

      Covers the combination of DHODH inhibitors and nucleoside analogues to treat viral infections, including Covid-19.
      09.22.21

    • Breaking News | Drug Development | Industry News
      Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

      Veklury Reduced Risk of Hospitalization in High-Risk COVID-19 Patients

      Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization.
      09.22.21


    • Breaking News | Clinical Trials
      First Patient is Dosed with Triumvira

      First Patient is Dosed with Triumvira's Investigational TAC-T Cell Adoptive Immunotherapy

      TAC01-HER2 was developed for the treatment of HER2-overexpressing cancers.
      09.21.21

    • Biologics, Proteins, Vaccines | Reader Showcase
      Thermo Fisher Launches Gibco AAV Production System

      Thermo Fisher Launches Gibco AAV Production System

      Aims to address the need to make adeno-associated virus (AAV) production more efficient and scalable.
      09.20.21

    Loading, Please Wait..
    Trending
    • Sarepta And Catalent Expand Manufacturing Partnership
    • Forge Biologics Strengthens Genetic Medicine CDMO Capabilities
    • Colorcon Signs Agreement To Purchase Airnov Healthcare Packaging
    • The Ongoing Evolution And Implementation Of DCTs In 2023
    • EyePoint Pharmaceuticals To Build GMP Mfg. Facility In Northbridge, MA
    Breaking News
    • Pasithea Signs CMC Development and Manufacturing Agreement
    • Experic Expands Analytical Capabilities and Facilities
    • List Labs Expands Manufacturing Capacity
    • groninger Continues Growth in the US
    • Catalent Bolsters Cell and Gene Services
    View Breaking News >
    CURRENT ISSUE

    November/December 2022

    • Cold Chain Packaging and Logistics
    • Optimizing Supply Chains for Allogeneic Cell Therapy Trials
    • Sustainable Manufacturing
    • Bioprocessing Trends
    • How Artificial Intelligence and Machine Learning are Transforming the Life Sciences
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Vitamin D Supplementation Reduces Risk of Dynapenia
    Sustained-Release Caffeine Ingredient Offers Mood, Performance Benefits
    Multi-Strain Probiotic Improves Self-Reported Mood, Sleep, Serotonin Levels
    Coatings World

    Latest Breaking News From Coatings World

    Epoxytec Announces New Website Launch
    Paints and Coatings Market Worth $212B by 2026: MarketsandMarkets
    Axalta Releases Fourth Quarter and Full Year 2022 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BMP Medical Expands Sterling, Massachusetts Facility
    Abbott's Proclaim XR SCS OK'ed for Diabetic Neuropathy
    Environmental Sustainability Becoming Increasingly Important to Medtech Industry
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pasithea Signs CMC Development and Manufacturing Agreement
    Experic Expands Analytical Capabilities and Facilities
    List Labs Expands Manufacturing Capacity
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Haircare Brand Uncle Funky’s Daughter Announces Retail Expansion
    TRESemmé Introduces New Pro Infusion Collection
    Walgreens Boots Alliance Shares 2022 ESG Report
    Happi

    Latest Breaking News From Happi

    KimChi Beauty Launches Spinning Hearts Love 02 Ahead of Valentine’s Day
    Dark & Lovely Names Actress Meagan Good Brand Ambassador
    Natural Household Care Company Tru Earth Adds Dishwasher Detergent Tablets
    Ink World

    Latest Breaking News From Ink World

    Xerox Releases 4Q, Full-Year 2022 Results
    Electronics For Imaging Names Frank Pennisi as CEO
    Fiery to Separate from EFI, Remain Wholly-Owned by Siris
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    EFI appoints Frank Pennisi CEO, Fiery now an independent business
    Bobst boosts senior sales team with Keith Nagle
    Penmar Industries adds Screen Truepress Jet L350UV SAI digital press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Essity’s Sales Grow
    Thinx to Pay up to $5 million to Settle Class Action Suit
    Typar Highlighting New Building Innovations
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Orthofix Launches the Mariner Deformity System
    Tyber Medical Hires 2 New Execs
    Miach Ortho Raises $40M in Series B Funding
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Smart Devices with Privacy Focus Have More Consumer Appeal
    Siman Group Partners with SML to Unlock Full Retail Potential with RFID
    Brewer Science Presents Optics Integration Solutions at SPIE Photonics West

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login